Plain-language guide to Arizona’s psilocybin, MDMA, and psychedelic laws — what’s legal, what isn’t, and what may change.
HB 2759 (2024) appropriated $5M for psilocybin research at Arizona universities; separate ibogaine interest via veterans-focused legislation.
Arizona funded $5M in psilocybin research at state universities through HB 2759 (2024), but this is a research appropriation, not a consumer access program. Psilocybin mushrooms are Schedule I under Arizona Revised Statutes §13-3401 and federal law. No decriminalization has passed; the research-to-access pipeline is expected to evolve as the university research matures.
As of 2026, Arizona does not have a licensed psilocybin access program. Legal options for residents include:
No. Psilocybin is a Schedule I controlled substance under Arizona Revised Statutes §13-3401. No state-level decriminalization has passed. No Arizona city has enacted a deprioritization resolution. Arizona's HB 2759 (2024) appropriated $5M for psilocybin research at state universities, but that is a grant to researchers, not a pathway for public access.
No. Neither Phoenix, Scottsdale, Tempe, nor any other Arizona city has passed a decriminalization or deprioritization resolution for psilocybin mushrooms. Arizona state law (Schedule I) applies throughout the state.
HB 2759 (2024) directed $5 million to Arizona public universities to study psilocybin for PTSD, depression, and addiction. A separate HB 2487 (2025) would create a therapeutic services access model, but has not passed. The research program places Arizona ahead of many states in the pipeline but behind Oregon and Colorado in actual consumer access.
No. Sedona is a popular destination for wellness retreats, but psilocybin remains Schedule I in Arizona. Retreat operators in the Sedona area who offer 'mushroom ceremonies' operate outside the law under both Arizona and federal law.